Hematopoietic stem cells for multiple sclerosis

The aim of this study is to assess the safety and feasibility of autologous peripheral hematopoietic stem cell transplantation in patients with multiple sclerosis, following patient conditioning with high-dose cyclophosphamide and anti-thymocyte globulin. Treatment reversed neurological deficits subsequent and in correlation to improvements in quality of life.